Biocon first-quarter profit jumps more than fourfold as biosimilars revenue rises 17%

The Indian biopharmaceutical company said biopharma, which makes up 83% of overall revenue, drove results while services revenue declined and expenses rose 8.7%.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.